A photo of Bradley Keller.

Co-Director, Greater Louisville and Western KY Practice, Heart Institute

Professor, UC Department of Pediatrics


Board Certified

My Biography & Research


Dr. Keller is a clinician-investigator who provides care to children and adults with congenital heart disease throughout Kentucky. He is also an expert in the causes of congenital heart disease and in the development and testing of novel technologies for children and adults with heart disease. On March 1, 2020, Dr. Brad Keller joined the Cincinnati Children's Heart Institute and Dr. Juan Villafañe, as co-director of Cincinnati Children’s Heart Institute – Greater Louisville and Western Kentucky practices, and is at our offices throughout the region. He brings more than 30 years of clinical and administrative congenital heart care experience including prior roles as division chief of Pediatric Cardiology at the University of Kentucky and at the Children’s Hospital of Pittsburgh.

Clinical Interests

Pediatric and adult congenital heart disease

Research Interests

Clinical translation of outpatient telemedicine

Academic Affiliation

Professor, UC Department of Pediatrics


Adolescent and Adult Congenital Heart Disease, Heart Institute, Cardiology Clinic, Heart Institute

My Education

Pediatric Cardiology Fellowship: University of Rochester Medical Center, Rochester, NY, 1988-1991.

Pediatric Residency: Johns Hopkins Hospital, Baltimore, MD, 1985-1988.

MD: Pennsylvania State University School of Medicine, Hershey, PA, 1981-1985.

BS: University of Pennsylvania, Philadelphia, PA, 1977-1981.

My Publications

Nrf2: Redox and Metabolic Regulator of Stem Cell State and Function. Dai, X; Yan, X; Wintergerst, KA; Cai, L; Keller, BB; Tan, Y. Trends in Molecular Medicine. 2020; 26:185-200.

Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury. Zhen, J; Yu, H; Ji, H; Cai, L; Leng, J; Keller, BB. Life Sciences. 2019; 239:117070-117070.

Chronic optical pacing conditioning of h-iPSC engineered cardiac tissues. Dwenger, M; Kowalski, WJ; Ye, F; Yuan, F; Tinney, JP; Setozaki, S; Nakane, T; Masumoto, H; Campbell, P; Guido, W; et al. Journal of Tissue Engineering. 2019; 10:2041731419841748-204173141984174.

Utilizing Contrast-Enhanced Ultrasound Imaging for Evaluating Fatty Liver Disease Progression in Pre-clinical Mouse Models. Pandit, H; Tinney, JP; Li, Y; Cui, G; Li, S; Keller, BB; II, MR C G. Ultrasound in Medicine and Biology. 2019; 45:549-557.

Right ventricular dysfunction and remodeling in diabetic cardiomyopathy. Kang, Y; Wang, S; Huang, J; Cai, L; Keller, BB. American Journal of Physiology: Heart and Circulatory Physiology. 2019; 316:H113-H122.

Asymmetry in Mechanosensitive Gene Expression during Aortic Arch Morphogenesis. Karakaya, C; Goktas, S; Celik, M; Kowalski, WJ; Keller, BB; Pekkan, K. Scientific Reports. 2018; 8.

Neonatal Murine Engineered Cardiac Tissue Toxicology Model: Impact of Metallothionein Overexpression on Cadmium-Induced Injury. Yu, H; Ye, F; Yuan, F; Cai, L; Ji, H; Keller, BB. Toxicological Sciences (Elsevier). 2018; 165:499-511.

Adipose-derived cells improve left ventricular diastolic function and increase microvascular perfusion in advanced age. Kelm, NQ; Beare, JE; Yuan, F; George, M; Shofner, CM; Keller, BB; Hoying, JB; LeBlanc, AJ. PLoS ONE. 2018; 13:e0202934-e0202934.

Inhibition of p53 prevents diabetic cardiomyopathy by preventing early-stage apoptosis and cell senescence, reduced glycolysis, and impaired angiogenesis article. Gu, J; Wang, S; Guo, H; Tan, Y; Liang, Y; Feng, A; Liu, Q; Damodaran, C; Zhang, Z; Keller, BB; et al. Cell Death and Disease. 2018; 9.

Challenging cardiac function post-spinal cord injury with dobutamine. DeVeau, KM; Martin, EK; King, NT; Shum-Siu, A; Keller, BB; West, CR; Magnuson, DS K. Autonomic Neuroscience: Basic and Clinical. 2018; 209:19-24.